Showing results (831-840 of 1,826) with videos related to
Sort By:
Pageof 183
Journal of Addiction Medicine|June 3, 2024
Sleep as an Important Target or Modifier in Alcohol Use Disorder Clinical Treatment: Example From a Recent Gabapentin Randomized Clinical TrialMichaela Hoffman, Konstantin Voronin, Sarah W Book, et al.Journal of Addiction Medicine|November 10, 2023
A Brief Online Training to Address Pharmacists' Willingness to Dispense BuprenorphineDelesha Carpenter, Patricia Mashburn, Cheryl Viracola, et al.Journal of Addiction Medicine|November 7, 2023
Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist TreatmentsJoel Pidutti, Ari B Cuperfain, Eric Solway, et al.Journal of Addiction Medicine|November 7, 2023
Opioid Settlements: The Role for Addiction Medicine in Guiding Effective SpendingSara Whaley, Josh Sharfstein, Josh RisingJournal of Addiction Medicine|November 7, 2023
Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use DisorderAlexander J Haines, Katlyn C Wood, Jennifer L Costello, et al.Journal of Addiction Medicine|November 7, 2023
Phencyclidine Positivity on Urine Drug Screening in Patients Treated for Alcohol Withdrawal on a Dual-diagnosis Medically Assisted Withdrawal UnitPhilip R Wang, Samyukta Dore, Jeremy Weleff, et al.Journal of Addiction Medicine|November 7, 2023
Self-reported Xylazine Experiences: A Mixed-methods Study of Reddit SubscribersAnthony Spadaro, Karen O'Connor, Sahithi Lakamana, et al.Journal of Addiction Medicine|November 7, 2023
National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use DisordersChloe Deflorimonte, Viktorria Glissendorf, Julia Hofer, et al.Journal of Addiction Medicine|November 7, 2023
Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized TrialSrinivas B Muvvala, Geliang Gan, Kenneth L Morford, et al.Journal of Addiction Medicine|October 17, 2023
48-hour Induction of Transdermal Buprenorphine to Extended-release BuprenorphinePouya Azar, James S H Wong, Nickie Mathew, et al.Pageof 183